Moreover, targeting LPA1 could be an appealing strategy for the treatment of other microglia-mediated neuroinflammatory disorders, including Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. Here, LPAR1 is linked to early-onset autosomal dominant Alzheimer disease.